[Pharmacist-Led Shared Decision-Making in a Pediatric Patient with Crohn's Disease and Growth Failure: A Case Report].

IF 0.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Momoko Konaka-Yamamoto, Ikkou Hirata, Maho Hamaguchi, Yuki Ohta, Ryohkan Funakoshi
{"title":"[Pharmacist-Led Shared Decision-Making in a Pediatric Patient with Crohn's Disease and Growth Failure: A Case Report].","authors":"Momoko Konaka-Yamamoto, Ikkou Hirata, Maho Hamaguchi, Yuki Ohta, Ryohkan Funakoshi","doi":"10.1248/yakushi.25-00041","DOIUrl":null,"url":null,"abstract":"<p><p>Inflammatory bowel disease (IBD) is an illness of unknown etiology, leading to chronic intestinal inflammation. It is characterized by repeated periods of remission and relapse. In the current treatment of IBD, multiple therapeutic drugs are listed in the Japanese treatment guidelines. Therefore, selecting a drug that matches the patient's condition and lifestyle is important, and the treatment decisions should be made using shared decision-making (SDM). For children, there is no specific age at which decision-making becomes possible. Therefore, medical professionals must make appropriate assessments regarding their decision-making ability. Although SDM has been shown to be useful in adults, there are no reports of SDM use in children. In this case report, a pharmacist performed multiple SDM for a 15-year-old patient with Crohn's disease. The SDM process reflected the child's changing values, leading to the introduction and continuation of biologic agents, and addressing growth disorders after the disease activity was controlled. To our knowledge, this is the first reported case in which a pharmacist performed SDM based on the condition of a pediatric patient with IBD, effectively implemented treat-to-target strategies, and improved the growth disorder. This case demonstrates the importance of properly controlling disease activity in pediatric patients with IBD and highlights the important role of pharmacists in adjusting drug therapy to suit a child's condition.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":"145 10","pages":"857-862"},"PeriodicalIF":0.2000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1248/yakushi.25-00041","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Inflammatory bowel disease (IBD) is an illness of unknown etiology, leading to chronic intestinal inflammation. It is characterized by repeated periods of remission and relapse. In the current treatment of IBD, multiple therapeutic drugs are listed in the Japanese treatment guidelines. Therefore, selecting a drug that matches the patient's condition and lifestyle is important, and the treatment decisions should be made using shared decision-making (SDM). For children, there is no specific age at which decision-making becomes possible. Therefore, medical professionals must make appropriate assessments regarding their decision-making ability. Although SDM has been shown to be useful in adults, there are no reports of SDM use in children. In this case report, a pharmacist performed multiple SDM for a 15-year-old patient with Crohn's disease. The SDM process reflected the child's changing values, leading to the introduction and continuation of biologic agents, and addressing growth disorders after the disease activity was controlled. To our knowledge, this is the first reported case in which a pharmacist performed SDM based on the condition of a pediatric patient with IBD, effectively implemented treat-to-target strategies, and improved the growth disorder. This case demonstrates the importance of properly controlling disease activity in pediatric patients with IBD and highlights the important role of pharmacists in adjusting drug therapy to suit a child's condition.

[在患有克罗恩病和生长衰竭的儿科患者中,药剂师主导的共同决策:一例报告]。
炎症性肠病(IBD)是一种病因不明的疾病,导致慢性肠道炎症。它的特点是反复的缓解和复发。在目前IBD的治疗中,日本的治疗指南中列出了多种治疗药物。因此,选择符合患者病情和生活方式的药物非常重要,治疗决策应采用共享决策(SDM)。对于儿童来说,没有具体的年龄可以决定。因此,医疗专业人员必须对自己的决策能力进行适当的评估。虽然SDM已被证明对成人有用,但没有关于儿童使用SDM的报道。在这个病例报告中,一名药剂师为一名15岁的克罗恩病患者进行了多次SDM。SDM过程反映了儿童价值观的变化,导致生物制剂的引入和延续,并在疾病活动得到控制后解决生长障碍。据我们所知,这是首次报道的药剂师根据IBD患儿的病情实施SDM,有效实施治疗到目标策略,改善生长障碍的病例。本病例显示了适当控制小儿IBD患者疾病活动性的重要性,并强调了药师在调整药物治疗以适应儿童病情方面的重要作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.60
自引率
0.00%
发文量
169
审稿时长
1 months
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信